MiNK Therapeutics (INKT) to Release Earnings on Tuesday

MiNK Therapeutics (NASDAQ:INKT) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect MiNK Therapeutics to post earnings of ($0.61) per share for the quarter.

MiNK Therapeutics (NASDAQ:INKT) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.12). On average, analysts expect MiNK Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MiNK Therapeutics Price Performance

Shares of MiNK Therapeutics stock opened at $7.53 on Tuesday. MiNK Therapeutics has a 1 year low of $4.56 and a 1 year high of $13.79. The firm’s 50-day moving average is $8.13 and its two-hundred day moving average is $7.91. The stock has a market cap of $29.86 million, a price-to-earnings ratio of -1.93 and a beta of 0.16.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of MiNK Therapeutics in a report on Tuesday, March 18th.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.